These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12390602)

  • 1. How better drugs could change kala-azar control. Lessons from a cost-effectiveness analysis.
    Boelaert M; Le Ray D; Van Der Stuyft P
    Trop Med Int Health; 2002 Nov; 7(11):955-9. PubMed ID: 12390602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.
    Vanlerberghe V; Diap G; Guerin PJ; Meheus F; Gerstl S; Van der Stuyft P; Boelaert M
    Trop Med Int Health; 2007 Feb; 12(2):274-83. PubMed ID: 17300636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of competing diagnostic-therapeutic strategies for visceral leishmaniasis.
    Boelaert M; Lynen L; Desjeux P; Van der Stuyft P
    Bull World Health Organ; 1999; 77(8):667-74. PubMed ID: 10516788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of diagnostic-therapeutic strategies for visceral leishmaniasis in Brazil.
    Assis TSM; Rabello A; Cota G; Werneck GL; Azeredo-da-Silva ALF
    Rev Soc Bras Med Trop; 2019 Apr; 52():e20180272. PubMed ID: 30994802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of visceral leishmaniasis.
    Sundar S; Rai M
    Expert Opin Pharmacother; 2005 Dec; 6(16):2821-9. PubMed ID: 16318433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The treatment of visceral leishmaniasis (kala-azar) in India: no obvious signs of long-term success.
    Muniaraj M; Paramasivan R; Mariappan T; Arunachalam N; Sinha PK
    Trans R Soc Trop Med Hyg; 2012 Dec; 106(12):770-2. PubMed ID: 23102868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine.
    Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S
    J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of Pediatric Visceral Leishmaniasis Care in Morocco.
    Tachfouti N; Najdi A; Alonso S; Sicuri E; Laamrani El Idrissi A; Nejjari C; Picado A
    PLoS One; 2016; 11(6):e0155482. PubMed ID: 27257808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment for human visceral leishmaniasis: a cost-effectiveness analysis for Brazil.
    de Carvalho IPSF; Peixoto HM; Romero GAS; de Oliveira MRF
    Trop Med Int Health; 2019 Sep; 24(9):1064-1077. PubMed ID: 31278808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and emerging medications for the treatment of leishmaniasis.
    Chakravarty J; Sundar S
    Expert Opin Pharmacother; 2019 Jul; 20(10):1251-1265. PubMed ID: 31063412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of humanitarian relief interventions: visceral leishmaniasis treatment in the Sudan.
    Griekspoor A; Sondorp E; Vos T
    Health Policy Plan; 1999 Mar; 14(1):70-6. PubMed ID: 10351471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elimination of Kala-Azar from the Southeast Asia Region.
    Bhattacharya SK; Dash AP
    Am J Trop Med Hyg; 2017 Apr; 96(4):802-804. PubMed ID: 28115678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visceral leishmaniasis control: a public health perspective.
    Boelaert M; Criel B; Leeuwenburg J; Van Damme W; Le Ray D; Van der Stuyft P
    Trans R Soc Trop Med Hyg; 2000; 94(5):465-71. PubMed ID: 11132368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal combinations of control strategies and cost-effective analysis for visceral leishmaniasis disease transmission.
    Biswas S; Subramanian A; ELMojtaba IM; Chattopadhyay J; Sarkar RR
    PLoS One; 2017; 12(2):e0172465. PubMed ID: 28222162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009].
    Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P
    Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India.
    Singh N; Chatterjee M; Sundar S
    Parasit Vectors; 2014 Dec; 7():596. PubMed ID: 25515494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug regimens for visceral leishmaniasis in Mediterranean countries.
    Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
    Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leishmaniasis: an update of current pharmacotherapy.
    Sundar S; Chakravarty J
    Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India.
    Olliaro P; Darley S; Laxminarayan R; Sundar S
    Trop Med Int Health; 2009 Aug; 14(8):918-25. PubMed ID: 19563434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
    Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.